The Efficacy and Safety of Alemtuzumab in Auotoimmune Cytopenias
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00472433
Recruitment Status :
(no eligible patient)
The majority of cases of autoimmune cytopenias, which includes immune thrombocytopenia (ITP), autoimmune hemolytic anemia, autoimmune neutropenia (AIN) and pure red cell aplasia, will respond to conventional immunosuppressive therapy with or without splenectomy. There is, however, a group of patients with refractory or chronically relapsing autoimmune cytopenias causing life-threatening hemorrhages, infections or anemia. Further problems include the short- and long-term side-effects of corticosteroids, and the potential toxicity of immunosuppressive and cytotoxic agents. An alternative and less toxic approach in these patients may be the treatment with Campath-1H, a humanized IgG monoclonal antibody specific for the CD52 antigen and present on human lymphocytes and monocytes. The main effect of Campath-1H is on T cell and it results in a prolonged and profound depletion of the CD4 and CD8 subpopulations, particularly the CD4 population, and this might "reset" the immune system without the need for total immune ablation.Therefore, this study is designed to investigate safety and efficacy of repeated Campath treatment cycles in autoimmune cytopenia.In order to minimize possible side effects of accumulating Campath, the 3 treatment cycles will be administered in consecutively reduced doses.
To investigate the efficacy of alemtuzumab in terms of objective response rate (ORR: complete remission [CR], partial remission [PR]), progression free survival (PFS), and relapse rate in patients with autoimmune cytopenias
Secondary Outcome Measures :
To determine the safety profiles of alemtuzumab in patients with autoimmune cytopenias.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients must have a diagnosis of the following autoimmune cytopenias:
immune thromobocytopenia purpura (ITP) autoimmune hemolytic anemia (AIHA) autoimmune neutropenia (AIN) pure red cell aplasia (PRCA) and
Patients must have refractory disease according to the following criteria
not respond to steroids or
need prednisolone more than 15 mg/d for maintenance therapy
Complete work up for baseline evaluation and measurement
Age > 18 years
Patient's free written inform consent
Patients with a known hypersensitivity to murine proteins or to any component of alemtuzumab
Patients with poor performance status (ECOG criteria of 3-4)
Serologic evidence of human immunodeficiency virus exposure
Patients with active uncontrolled infection. Patients that are HIV positive or test positive on HBs or HCV antigens.
Pregnant or lactating women
Serious medical or psychiatric illness which prevent informed consent
Patients who are likely to lost to follow up (eg, unwilling or difficult to return, cannot be contacted)